VFC's Stock House: Synergy Pharmaceuticals (SGYP) Ready To Roll
(EMAILWIRE.COM, May 22, 2012 ) New York, NY -- VFC's Stock House, an information and research outlet that brings ideas and opens discussions to a broad spectrum of investors, reported today that Synergy Pharmaceuticals (SGYP) may be in a position to realize significant share price gains over the coming months.
Synergy Pharmaceuticals (SGYP) ran to over seven dollars last month on increasing volume as the company's billion dollar potential took shape and numerous analysts jumped on board with encouraging write-ups and bold price predictions.
Synergy also received a boost when its chief competitor, Ironwood Pharmaceuticals (IRWD) received a setback at the FDA that allows SGYP an extra three months to play catch up in the race to commercialization for each company's respective product candidate, both of which target the same indication. Synergy's product Plecanatide, however, has a much more favorable side effect profile, making the Ironwood setback that much more of a key factor when discussing future market potential.
Both products, Synergy's Plecanatide and Ironwood's Linaclotide, are being developed to treat chronic idiopathic constipation (CIC) and constipation-predominant irritable bowel syndrome (IBS-C). Linaclotide is already before the FDA for review, although the review was delayed by three months, as mentioned before, while Phase II/III Plecanatide results are due out later this year.
The head start to market may provide Ironwood with a distinct advantage, but the advantage might not last too long when Plecanatide shows up on the scene.
During the Linaclotide trials, the drug was successful in alleviating symptoms relating to IBS-C and CIC when compared to a placebo, but the kicker is that patients experienced side effects that included cases of extreme diarrhea, essentially reversing the symptom being treated. Some cases of diarrhea were so bad that 6% of the patients decided to abandon the trial altogether.
On the open market - with a competing product out there for which there have been no such cases noted - that means those patients would likely switch to the alternative, in this case Plecanatide, that is not associated with carrying around a roll of Charmin' Soft at all times.
VFC's Stock House is an information and research outlet that brings new ideas to the table and opens discussions for a broad spectrum of investors, with a strong focus on - but not limited to - biotech stocks and the pharmaceutical and healthcare sectors. VFC's Stock House provides individual company profiles, write-ups and reports as well as giving general insights into broader-market news through various 'Stock Watch' lists. At the conclusion of most weeks, VFC's Stock House issues a "Weekly Stock Watch" that examines news items, stocks and stories that made headlines during the previous trading week, but may also make headlines or influence trends during the upcoming week as well. The information contained within the pages of VFCs Stock House are not intended to be taken as advice, but as a starting point where investors can follow up with their own DD and devise their own entry and exit strategies.